<DOC>
	<DOCNO>NCT02098837</DOCNO>
	<brief_summary>The purpose study investigate benefit switch away kind drug call boost protease inhibitor ( PI ) new drug call dolutegravir patient ' cardiovascular health ( health heart ) . Patients currently take two anti-HIV drug , call nucleoside reverse transcriptase inhibitor ( NRTIs ) , boost PIs ; NRTIs change throughout study . In order compare boost PI dolutegravir accurately , half study participant switch dolutegravir immediately , half switch 48 week continue boost PI . Boosted PIs associate increased heart circulation risk hop switch boost PI dolutegravir improve health patient ' heart . Dolutegravir drug HIV treatment approve use HIV patient US Europe . Clinical trial use dolutegravir find effective suppressing HIV virus , least effective drug . This study also investigate safety ( term side effect routine blood test investigator ordinarily use monitor patient ' treatment ) monitor effectiveness , patient ' viral load CD4 count , patient switch treatment boost PI dolutegravir . Viral load amount HIV virus blood , CD4 count measure type cell immune system . We also aim improve patient ' cardiovascular health general provide information live healthy lifestyle ( eg improve diet , stop smoke etc ) .</brief_summary>
	<brief_title>Cardiovascular Risk HIV Patients Switching From Boosted Protease Inhibitor ( PI ) Dolutegravir ( DTG )</brief_title>
	<detailed_description>Study Design : Randomised , non-inferiority strategic trial 96 week early delay switch ARV regimen contain boost PI plus 2 NRTIs dolutegravir ( DTG ) plus 2 NRTIs patient achieve complete virological suppression 24 week ( HIV-1 RNA &lt; 50 c/ml ) . Patients randomise switch baseline 48 week . Study visit take place screening , baseline , week 4 ( immediate switch group ) , 12 , 24 , 36 , 48 , 52 ( deferred switch group ) , 60 , 72 , 84 96 , plus follow visit 28 day last dose study medication . Routine investigation include viral load , CD4 , haematology ( include haemoglobin , white cell count differential , platelet ) , biochemistry ( include sodium , potassium , creatinine , albumin , glucose , ALT , ALP , total bilirubin , total cholesterol , HDL , LDL , triglyceride ) , quality life questionnaire ( EuroQL ) , urine sample ( haematuria , proteinuria , glycosuria , leukocytes , nitrate &amp; pregnancy test WOCBP )</detailed_description>
	<mesh_term>Dolutegravir</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<criteria>Patient volunteer meet follow criterion eligible trial : 1 . Is male female age 50 , OR age 18 year Framingham risk score 10 % 2 . Has document HIV1 infection 3 . Has sign Informed Consent Form voluntarily 4 . Is willing comply protocol requirement 5 . Has receive ARV regimen contain boost PI ( darunavir , atazanavir , lopinavir , fosamprenavir ) plus 2NRTIs &gt; 24 week 6 . Has stable virological suppression ( plasma HIVRNA &lt; 50 copies/mL &gt; 24 week ) 7 . If female childbearing potential , use effective birth control method willing continue practise birth control method trial least 2 week last dose study medication . Note : Nonchildbearing potential define either postmenopausal ( 12 month spontaneous amenorrhoea ≥45 year ) physically incapable become pregnant document tubal ligation , hysterectomy bilateral oophorectomy 8 . If heterosexually active male , use effective birth control method willing continue practise birth control method trial followup visit Patients meet 1 follow criterion select : 1 . Infected HIV2 2 . Using concomitant therapy disallow per reference safety information product labelling study drug 3 . Has acute viral hepatitis include , limited , A , B , C 4 . Has chronic hepatitis B and/or C AST and/or ALT &gt; 5 x ULN Note : Subjects enter trial chronic HBV HBVDNA undetectable screen ( detectable result last 6 month ) chronic HCV expect require treatment trial period . 5 . Any investigational drug within 30 day prior trial drug administration 6 . History exposure ARVs PIs NRTIs except switch tolerability/toxicity ( NOTE : patient previously take part single drug trial less 14 day need exclude , virological failure genotypic resistance test without mutation 7 . Any prior evidence primary viral resistance base presence major resistanceassociated mutation backbone NRTI 8 . History prior virological failure , eg 2 consecutive HIV1 RNA &gt; 50 c/ml week 32 follow first ART initiation confirm rebound viraemia &gt; 200 copies/ml VL &lt; 50 copies/ml without resistance test significant mutation ARV regimen ( NOTE : Switch toxicity tolerability wild type virus count virological failure ) 9 . Dialysis renal insufficiency ( creatinine clearance &lt; 50ml/min ) 10 . History decompensated liver disease ( AST ALT≥5x upper limit normal ( ULN ) ALT ≥ ) 3 x ULN bilirubin ≥ 1.5 x ULN &gt; 35 % direct bilirubin . 11 . Unstable liver disease ( define presence ascities , encephalopathy , coagulopathy , hypoalbuminemia , esophageal gastric varix , persistent jaundice ) , know biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) ) 12 . Subjects severe hepatic impairment ( Class C ) determine ChildPugh classification 13 . If female , currently pregnant breastfeed 14 . Opportunistic infection within 4 week prior first dose DTG 15 . Clinical decision switch antiretroviral therapy immediate 16 . Screening blood result grade 3/4 toxicity accord Division AIDS ( DAIDS ) grade scale , except : asymptomatic grade 3 glucose , amylase lipid elevation asymptomatic grade 4 triglyceride elevation ( retest allow ) . 17 . Any condition ( include illicit drug use alcohol abuse ) laboratory result , investigator 's opinion , interfere assessment completion trial . 18 . History presence allergy study drug component</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>HIV</keyword>
</DOC>